<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6473">
  <stage>Registered</stage>
  <submitdate>7/05/2017</submitdate>
  <approvaldate>7/05/2017</approvaldate>
  <nctid>NCT03146468</nctid>
  <trial_identification>
    <studytitle>Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation</studytitle>
    <scientifictitle>Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation</scientifictitle>
    <utrn />
    <trialacronym>NIVALLO</trialacronym>
    <secondaryid>RMH 2016.281</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Haematological Malignancy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nivolumab Injection

Experimental: Nivolumab treatment arm - Nivolumab injection 3mg/kg intravenously every 2 weeks


Treatment: drugs: Nivolumab Injection
Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Graft versus host disease - Cumulative incidence of graft versus host disease</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Graft versus host disease - Cumulative incidence of graft versus host disease</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Graft versus host disease - Cumulative incidence of graft versus host disease</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Complete remission and partial remission</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Complete remission and partial remission</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Complete remission and partial remission</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Complete remission and partial remission</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Prior allogeneic stem cell transplant for a haematological malignancy

          -  Confirmed relapse of haematological malignancy or persistent disease post-alloSCT

          -  Immunosuppression cessation for minimum of 2 weeks

          -  Life expectancy &gt; 2 months

          -  ECOG performance status 0-2

          -  Greater than or equal to 30% CD3+ donor chimerism

          -  Serum creatinine = 1.5 times upper limit of normal OR creatinine clearance = 40mL/min

          -  AST and ALT = 3 times upper limit of normal

          -  Total bilirubin = 1.5 times upper limit of normal (except patients with Gilbert
             Syndrome)

          -  Signed written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current evidence of any grade of GVHD

          -  Prior history of grade 2 or higher acute GVHD

          -  Moderate chronic GVHD within the previous 6 months or any prior history of severe
             chronic GVHD

          -  Active, known or suspected autoimmune disease (excluding vitiligo, type 1 diabetes
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to
             recur in the absence of an external trigger)

          -  Positive hepatitis B virus surface antigen

          -  Positive hepatitis C virus antibody

          -  Known human immunodeficiency virus infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>8/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>14</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective study of the safety and efficacy of nivolumab for the treatment of
      relapsed or residual haematological malignancies after allogeneic stem cell transplantation
      (alloSCT).

      Eligible patients will receive nivolumab at a dose of 3mg/kg intravenously every 2 weeks. The
      primary objective is to evaluate the incidence, severity and treatment responsiveness of GVHD
      following nivolumab treatment post-alloSCT.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03146468</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Ritchie, FRACP, PhD</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>David Ritchie, FRACP, PhD</name>
      <address />
      <phone>+61 3 93422520</phone>
      <fax />
      <email>david.ritchie@mh.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>